维生素D联合胸腺五肽对慢阻肺急性加重期患者肺功能、血气指标及6min步行距离的影响探讨  

Effect of Vitamin D Combined with Thymopentin on Pulmonary Function,Blood Gas Index and Walking Distance of 6 Min in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

作　　者：黄敏[1] 林少芳[1] 朱云华[1] HUANG Min;LIN Shao-fang;ZHU Yun-hua(Department of Geriatrics, Kunming First People's Hospital, Kunming, Yunnan Province, 650000 China)

机构地区：[1]昆明市第一人民医院老年病科,云南昆明650000

出　　处：《中外医疗》2019年第8期19-22,共4页China & Foreign Medical Treatment

摘　　要：目的研讨采用维生素D+胸腺五肽治疗慢阻肺急性加重期患者对其肺功能、血气指标和6 min步行距离的具体影响。方法方便选取该院2015年1月—2017年5月接收的74例慢阻肺急性加重期患者作为对象,按治疗方案的差异将其分成试验组和参照组,各组37例,试验组采用维生素D+胸腺五肽对患者进行联合治疗,参照组单独采用维生素D对患者进行治疗,评估两组患者肺功能、血气指标、6 min步行距离及相关指标的差异性。结果治疗后,肺功能指标方面,试验组患者FEV_(1.0)(2.9±0.39)L、FEV_(1.0)%预计值(60.3±12.89)%、FEV_(1.0)/FVC(60.8±10.25)%显著高于参照组的FEV_(1.0)(1.9±0.57)L、FEV_(1.0)%预计值(51.2±12.47)%、FEV_(1.0)/FVC(40.2±9.24)%,组间差异有统计学意义(P<0.05)。血气指标方面,试验组PaO_2(93.5±10.17)mmHg、PaCO_2(30.8±4.18)mmHg,参照组PaO_2(84.2±8.25)mmHg、PaCO_2(40.5±5.17)mmHg,试验组患者PaO_2指标显著高于参照组,而PaCO_2指标显著低于参照组(P<0.05)。另外,试验组患者治疗后6 min步行距离(405.2±55.83)m、急性加重次数(0.9±0.75)次、住院天数(12.5±2.84)d,参照组患者治疗后6 min步行距离(352.8±42.78)m、急性加重次数(2.2±1.23)次、住院天数(2.2±1.23)d,和参照组患者相比,试验组患者治疗后6 min步行距离显著更长,急性加重次数显著更少,住院天数显著更短(t=4.532、5.489、5.813,P<0.05)。结论将维生素D+胸腺五肽联合用于慢阻肺急性加重期患者的治疗中,可显著改善患者肺功能指标和血气指标,有助于延长患者6 min步行距离,并能减少急性加重次数和住院天数,使患者尽快减轻病痛,效果较佳。Objective To investigate the specific effects of vitamin D+ thymopentin on the lung function, blood gas index and walking distance of 6 min in patients with acute exacerbation of chronic obstructive pulmonary disease. Methods Con-venient select 74 patients with acute exacerbation of chronic obstructive pulmonary disease received from January 2015 to May 2017 were enrolled in the study. They were divided into the experimental group and the reference group according to the difference of treatment options. 37 patients in each group, the test group used vitamins D + thymopentin to treat patients in combination. The reference group was treated with vitamin D alone. The differences in lung function, blood gas index, 6- minute walking distance and related indicators were evaluated. Results After treatment, the lung function index, the experi-mental group patients FEV1.0 (2.9±0.39) L, FEV1.0% predicted value (60.3 ±12.89)%, FEV1.0/FVC (60.8±10.25)% signifi-cantly higher than the reference group of FEV1.0 (1.9±0.57)L, FEV1.0% predicted value (51.2±12.47)%, and FEV1.0/FVC (40.2±9.24%) were statistically significant (P<0.05). In terms of blood gas index, the experimental group PaO2 (93.5±10.17)mmHg, PaCO2 (30.8±4.18) mmHg, reference group PaO2 (84.2±8.25) mmHg, PaCO2 (40.5±5.17) mmHg, the PaO2 index of the test group was significantly higher than the reference group. The PaCO2 index was significantly lower than the reference group (P<0.05). In addition, the walking distance of the experimental group was 6 min (405.2±55.83) m, the number of acute exacerbations (0.9±0.75)times, the length of hospital stay (12.5±2.84) d, and the walking distance of the reference group af-ter 6 min (352.8±42.78) m. The number of acute exacerbations (2.2±1.23)times and the length of hospital stay (2.2±1.23)d. Compared with the patients in the reference group, the walking distance of the experimental group was significantly longer 6 minutes after treatment, the number of acute exacerbations was significantly less, and the number o

关 键 词：慢阻肺 急性加重期 维生素D 胸腺五肽 肺功能指标 血气指标 6MIN步行距离 

分 类 号：R563.9[医药卫生—呼吸系统]